Literature DB >> 12109997

Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure.

Hartmut H Malluche1, Hanna Mawad, Nicholas J Koszewski.   

Abstract

Vitamin D is an important hormone for mineral homeostasis and the proper formation and maintenance of bone. In addition, vitamin D has broader functions in the body that expand its traditionally known role in mineral balance. In chronic renal failure, calcitriol deficiency contributes to the development and progression of secondary hyperparathyroidism, bone disorders, and altered mineral metabolism. Recent revelations of the broader role of vitamin D also suggest calcitriol deficiency may contribute to decreased cardiac and immune function in chronic renal failure patients. Research on vitamin D has led to a more complete understanding of the actions of vitamin D at the transcriptional level and with respect to the clinical use of vitamin D and its analogs to control parathyroid hormone overactivity and to replace the other D hormone-dependent actions in patients with renal failure. Limitations of vitamin D and its metabolites include hypercalcemia, hyperphosphatemia and suppression of bone turnover with the risk of adynamic bone disease. Vitamin D analogs may offer greater selectivity and potentially greater safety as compared to calcitriol because of their altered relative potency on calcium and phosphorus metabolism. This review focuses on the current understanding of the biological actions of vitamin D and its analogs and the rationale for treating patients with chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109997     DOI: 10.1046/j.1523-1755.2002.00450.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy.

Authors:  Manabu Okada; Yoshihiro Tominaga; Takahisa Hiramitsu; Toshihiro Ichimori
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

Review 2.  Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).

Authors:  M Maggi; C Crescioli; A Morelli; E Colli; L Adorini
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

Review 3.  Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes.

Authors:  Claudio Ronco; Mario Cozzolino
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

4.  Treatment of Hyperparathyroidism (SHPT).

Authors:  Fabiana Rodrigues Hernandes; Patrícia Goldenstein; Melani Ribeiro Custódio
Journal:  J Bras Nefrol       Date:  2021-12-03

Review 5.  Public health approach to addressing hyperphosphatemia among dialysis patients.

Authors:  Ashwini R Sehgal; Catherine Sullivan; Janeen B Leon; Karil Bialostosky
Journal:  J Ren Nutr       Date:  2008-05       Impact factor: 3.655

6.  Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells.

Authors:  Jorge N Artaza; Keith C Norris
Journal:  J Endocrinol       Date:  2008-11-26       Impact factor: 4.286

7.  1,25(OH)2vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells.

Authors:  Jorge N Artaza; Fara Sirad; Monica G Ferrini; Keith C Norris
Journal:  J Steroid Biochem Mol Biol       Date:  2010-01-11       Impact factor: 4.292

8.  Vitamin D receptor gene BsmI polymorphisms in Thai patients with systemic lupus erythematosus.

Authors:  Wilaiporn Sakulpipatsin; Oravan Verasertniyom; Kanokrat Nantiruj; Kitti Totemchokchyakarn; Porntawee Lertsrisatit; Suchela Janwityanujit
Journal:  Arthritis Res Ther       Date:  2006-02-20       Impact factor: 5.156

9.  Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.

Authors:  Chia-Yu Hsu; Li-Ru Chen; Kuo-Hu Chen
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.